Auro Laboratories Ltd

Auro Laboratories, a microcap in the Pharmaceuticals & Drugs sector, has recently experienced a change in evaluation due to various financial metrics and market conditions. The company reported a significant decline in net sales and profit after tax for the second quarter of FY24, alongside a low debt-to-equity ratio and strong management efficiency.

Auro Laboratories has recently experienced a change in evaluation, reflecting its current market conditions and operational performance. Despite facing challenges in long-term growth and a decline in net sales, the company demonstrates strong management efficiency and a conservative financial strategy, alongside a significant return over the past year.

Auro Laboratories has recently undergone a revision in its stock evaluation by MarketsMOJO, reflecting ongoing challenges in its financial performance. Despite a significant decline in net sales and profit after tax, the company has been added to MarketsMOJO's list, highlighting its management efficiency and low debt-to-equity ratio.

Auro Laboratories has recently undergone a revision in its score from MarketsMOJO, reflecting the company's strong management efficiency and positive technical indicators. Despite recent negative quarterly results, the stock has demonstrated impressive performance over the past year, outperforming the BSE 500 index and being added to MarketsMOJO's list.

Auro Laboratories, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to its poor long-term growth and negative results in September 2024. However, the company has shown high management efficiency and its stock is currently trading at a fair value with positive technical indicators. Investors are advised to do their own research before making any decisions.

Auro Laboratories, a microcap pharmaceutical company, has reported a negative performance in the second quarter of fiscal year 2024-2025. While the company has shown strong operating cash flow and consistent growth over the past three years, there are concerning factors such as a decrease in net sales and profits. Investors should carefully evaluate before investing.

Auro Laboratories, a microcap pharmaceutical company, has reported a flat performance in the quarter ending March 2024, with a score of -1. The company's operating cash flow has been consistently growing, but net sales and profit after tax have seen a significant decrease. Investors are advised to hold their stock and monitor future financial reports.

Auro Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on May 7th, 2024. The stock has been given a 'Hold' rating by MarketsMOJO and has outperformed the sector in the past year. The company's strong performance and focus on affordable medicines make it a promising player in the industry.

Auro Laboratories, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching an all-time high of Rs.307.2 on May 7, 2024. The company's stock has been on a consecutive upward trend for the past 7 days, with a remarkable 53.26% increase in returns. Its strong performance and potential for future success make it a company to watch in the microcap sector.

The stock has reached a 52-week high, with a consecutive gain for the last 6 days and a rise of 45.97%. It is currently trading higher than all its moving averages and has shown an impressive 1-year performance of 346.44%, outperforming the Sensex. MarketsMOJO recommends holding onto current positions in the stock.

Auro Laboratories, a microcap pharmaceutical company, has seen a significant rise in its stock price, reaching an all-time high on May 6th, 2024. The stock has been on a steady upward trend for the past 6 days, outperforming the sector by 4.99%. With consistently strong performance and a remarkable 1-year return of 346.44%, Auro Laboratories shows potential for growth in the pharmaceutical industry.

Auro Laboratories, a microcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high of Rs.278.7 on May 5th, 2024. The stock has outperformed its sector and is trading higher than its moving averages, with a 1-year performance of 324.46% compared to the Sensex's 20.73%.

Auro Laboratories, a microcap pharmaceutical company, has been in the spotlight as its share price reached an all-time high on May 4th, 2024. With a consecutive upward trend for the past 5 days and a gain of 39.04%, the stock has outperformed the sector by 9.88%, making it a top performer. Its strong financials and consistent performance have contributed to its impressive growth of 324.46% in the past year, outperforming the Sensex. MarketsMOJO has given a 'Hold' call for the stock, indicating a neutral stance.

Auro Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on May 3, 2024. The stock has gained 38.14% in just 5 days and is currently rated as 'Hold' by MarketsMOJO. It has outperformed the sector and is trading above its moving averages, showcasing its strong performance and potential for growth.

Auro Laboratories, a microcap pharmaceutical company, has seen a significant increase in its share price, reaching an all-time high of Rs. 270 on May 3rd, 2024. According to MarketsMOJO, the stock call for Auro Laboratories is 'Hold', indicating positive performance but not the best time to buy or sell. The stock has outperformed its sector by 6.55% today and has been on a consecutive gain streak for the last 5 days. Auro Laboratories is also trading higher than its moving averages and has shown an impressive 321.57% increase in the last year, highlighting its strong performance and potential for growth in the pharmaceutical industry.

Auro Laboratories, a microcap pharmaceutical company, has been making headlines in the stock market with its stock price reaching a 52-week high on May 2, 2024. The stock has been on an upward trend, outperforming the sector by 2.59% and consistently trading higher than its moving averages. With a 1-year performance of 255.52%, Auro Laboratories is a company to watch out for in the pharmaceutical industry.

Auro Laboratories, a microcap pharmaceutical company, has reached an all-time high stock price on May 2nd, 2024. It has been given a 'Hold' rating by MarketsMOJO and is currently trading 2.13% below its 52-week high. The company has shown impressive growth of 259.09% in the past year, outperforming the Sensex.

Auro Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on May 1st, 2024. Its stock has outperformed the sector by 8.27% and is trading higher than all its moving averages. With a remarkable 1-year performance of 259.89%, Auro Laboratories shows strong potential in the pharmaceutical industry.

Auro Laboratories, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on April 30th, 2024. The stock has outperformed the sector by 6.41% and has shown consecutive gains for the last 3 days. It is currently trading higher than its moving averages, indicating a positive trend. With a 260.82% increase in the past year and a 'Hold' rating from MarketsMOJO, Auro Laboratories shows potential for growth in the pharmaceutical industry.